Inspira outline transaction framework for breast cancer liquid biopsy expansion

Inspira Technologies (IINN) outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company’s core respiratory and life-support technologies. Tal Parnes, Chairman of the Board of Inspira Technologies, stated: “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a high-impact diagnostics capability with substantial long-term potential. The Board and management have deliberately structured this transaction to pursue this growth opportunity while optimally allocating value between the new platform and Inspira’s core respiratory business through a CVR framework. We view this as disciplined, strategic value creation designed to maximize upside across both platforms.”